Fractyl

Lexington, United States Founded: 2010 • Age: 16 yrs
Endoscopic procedures for type-2 diabetes treatment are developed.
Annual revenue $93,000 Latest available
Total funding $345.3M 7 rounds
Employees 107 Tracked headcount
Investors 18 Known backers
Products 2 Services tracked
Competitors 9 Brand Intelligence

About Fractyl

Fractyl is a company based in Lexington (United States) founded in 2010. Fractyl has raised $345.27 million across 7 funding rounds from investors including Bessemer Venture Partners, Maverick Ventures and M28 Capital. The company has 107 employees as of December 31, 2024. Fractyl offers products and services including Revita and Rejuva. Fractyl operates in a competitive market with competitors including Adocia, BioAge Labs, Antag Therapeutics, Carmot and Altimmune, among others.

  • Headquarter Lexington, United States
  • Employees 107 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Fractyl Health, Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $93 K (USD)
    -22.5
    as on Dec 31, 2024
  • Net Profit
    -$68.69 M (USD)
    10.89
    as on Dec 31, 2024
  • EBITDA
    -$92.85 M (USD)
    -83.69
    as on Dec 31, 2024
  • Total Equity Funding
    $345.27 M (USD)

    in 7 rounds

  • Latest Funding Round
    $100 M (USD), Series F

    Jun 16, 2021

  • Investors
  • Employee Count
    107

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Fractyl

Fractyl is a publicly listed company on the NASDAQ with ticker symbol GUTS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NASDAQ · Ticker: GUTS · Sector: Health technology · USA

Products & Services of Fractyl

Fractyl offers a comprehensive portfolio of products and services, including Revita and Rejuva.

Product name locked
Category locked
Primary

Outpatient procedure to resurface duodenum for obesity root cause treatment

Product name locked
Category locked
Locked

Platform for long-term remission of obesity and type 2 diabetes

People of Fractyl

Headcount 50-200
Employee Profiles 44
Board Members and Advisors 6
Employee Profiles
People
Lindsay Schulman
Principal Associate Scientist
People
Carley Balbuena
Associate Director Human Resources
People
Sarah Toomey
General Counsel & Corporate Secretary
People
Harith Rajagopalan
Co-Founder & CEO

Unlock access to complete

Funding Insights of Fractyl

Fractyl has successfully raised a total of $345.27M across 7 strategic funding rounds. The most recent funding activity was a Series F round of $100 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Fractyl

Fractyl has secured backing from 18 investors, including venture fund and institutional investors. Prominent investors backing the company include Bessemer Venture Partners, Maverick Ventures and M28 Capital.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Early-stage tech and life-sciences firms are funded across the US.
Locked Locked Locked
A firm focused on biotechnology investments for prevalent diseases is operated.
Locked Locked Locked
VC firm focusing on technology companies
Locked Locked Locked
Premium access

Investor details for Fractyl

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Fractyl

Investments
Premium access

Investment portfolio details for Fractyl

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Fractyl

Premium access

Detailed financials for Fractyl

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Fractyl Comparisons

Fractyl Primary company
Description
Endoscopic procedures for type-2 diabetes treatment are deve...
Location
Lexington, United States
Founded Year
2010
Annual Revenue
$93 K (USD)
Net Profit
-$68.69 M (USD)
EBITDA
-$92.85 M (USD)
Employees
107
As of 2024
Premium access

Peer comparison for Fractyl

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Fractyl

Fractyl operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adocia, BioAge Labs, Antag Therapeutics, Carmot and Altimmune, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Therapeutics for diabetes and obesity treatment are developed.
Locked Locked Locked
Bioinformatics platform is provided for biomarkers and drug discovery.
Locked Locked Locked
Peptide-based therapies for obesity and cardiometabolic disorders are developed.
Locked Locked Locked
Disease-modifying therapies for metabolic diseases are developed.
Locked Locked Locked
Vaccines for infectious diseases and solid tumors are developed.
Premium access

Detailed competitors of Fractyl

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Fractyl

Premium access

Complete news archive for Fractyl

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Fractyl

Fractyl was founded in 2010 and raised its 1st funding round 3 years after it was founded.

Fractyl is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.

Fractyl is a funded company, having raised a total of $345.27M across 7 funding rounds to date.

As of Dec 31, 2024, the latest employee count at Fractyl is 107.

Annual revenue of Fractyl is $93K as on Dec 31, 2024.

Fractyl was founded in 2010 and is headquartered in Lexington, United States. Operations focus on the medical device sector, where an investigational trans-oral procedure called Revita duodenal mucosal resurfacing (DMR) is developed to address type-2 diabetes. The procedure, performed via the proprietary Revita System, involves hydrothermal ablation of the duodenal lining to influence glucose control and insulin resistance. A console and single-use balloon catheter are utilized in the process.

Fractyl's top competitors include Adocia, BioAge Labs and Carmot.

Fractyl offers Revita and Rejuva.

Yes, Fractyl is publicly traded on NASDAQ under the ticker symbol GUTS.

The ticker symbol of Fractyl is GUTS on NASDAQ.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available